Slide 1: 1st Quarter 2025 Earnings Release Supplemental Information
04.24.25 st 1 Quarter 2025 Earnings Release Supplemental Information
Slide 2: Safe Harbor
Safe Harbor Forward Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, such as statements about our future plans, objectives, expectations, financial performa
Slide 3: Q1 2025 Results
Q1 2025 Results First Quarter Results at Revenue of or above expectations $132 million ◦ Revenue is at the high end of our guided range, down slightly from a year ago. Non-GAAP Diluted EPS* ◦ Non-GAAP Diluted EPS was at the mid-point of $0.18 our guided range, flat to the prior year. ◦ Cash from ope
Slide 4: Q1 2025 Segment Performance: MedTech & Specialty Audio
Q1 2025 SEGMENT PERFORMANCE Revenue Adjusted EBITDA Margin* ($M) (%) MedTech & Specialty Audio 43.7 39.2 • Revenue grew slightly year over year on higher 59.0 59.7 demand in specialty audio. • Adjusted EBITDA margins were down 450 bps year over year driven by unfavorable customer mix, -450 one-time
Slide 5: Q1 2025 Segment Performance: Precision Devices
Q1 2025 SEGMENT PERFORMANCE Revenue Adjusted EBITDA Margin* ($M) (%) 74.3 Precision Devices 72.5 16.8 18.2 • Revenue was down year over year. This was expected while we continue to work through production challenges in our Specialty Film line. Year over year growth is expected to resume in the secon
Slide 6: Outlook: Q2 2025 Guidance
OUTLOOK Q2 2025 Guidance GAAP Adjustments Non-GAAP Revenues from continuing operations $135 to $145 million $— $135 to $145 million Diluted earnings per share from $0.11 to $0.15 $0.10 $0.21 to $0.25 continuing operations Net cash provided by operating activities $10 to $20 million $— $10 to $20 mil
Slide 7: Appendix
« knowles Appendix
Slide 8: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES Quarter Ended March 31, (continuing operations, in millions, except per share amounts) 2025 2024 Notes Revenues $ 132.2 $ 133.3 1. Production transfer costs represent duplicate costs incurred to migrate Gross profit $ 53.3 $ 53
Slide 9: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES Quarter Ended March 31, (continuing operations, in millions, except per share amounts) 2025 2024 Notes Net loss $ (0.4) $ (1.0) 5. The non-GAAP reconciling adjustments to reconcile Earnings before interest and Interest expense,
Slide 10: Historical Segment Data
HISTORICAL SEGMENT DATA PRECISION DEVICES MEDTECH & SPECIALTY AUDIO Quarter Ended Quarter Ended March 31, December 31, September 30, June 30, March 31, March 31, December 31, September 30, June 30, March 31, (continuing operations, in millions) 2025 2024 2024 2024 2024 2025 2024 2024 2024 2024 Reven
Slide 11: Historical Segment Data
HISTORICAL SEGMENT DATA PRECISION DEVICES MEDTECH & SPECIALTY AUDIO Quarter Ended Quarter Ended March 31, December 31, September 30, June 30, March 31, March 31, December 31, September 30, June 30, March 31, (continuing operations, in millions) 2025 2024 2024 2024 2024 2025 2024 2024 2024 2024 Reven
Slide 12: Adjusted EBITDA Reconciliation, Quarterly and Trailing 12 Months
Quarter Ended March 31, December 31, September 30, June 30, Trailing (Continuing operations, in millions) 2025 2024 2024 2024 12-months Net (loss) earnings $ (0.4) $ 10.4 $ 9.2 $ 4.8 $ 24.0 Interest expense, net 2.7 3.4 3.9 4.6 14.6 Provision for (benefit from) income taxes 1.2 3.3 3.0 3.0 10.5 Earn
Slide 13: Reconciliation of Net Debt
RECONCILIATION OF NET DEBT (in millions) March 31, 2025 Current maturities of long-term debt $ 69.8 Long-term debt 119.0 Total debt 188.8 Less: Cash and cash equivalents (101.9) Net debt $ 86.9 Net debt $ 86.9 Trailing 12 Month Adjusted EBITDA $ 126.7 Net debt leverage ratio 0.7 x 13
Slide 14: Thank you.
Thank you. « knowles